# A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

> **NCT07711184** · PHASE1 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** HRS-7525 tablets

## Key facts

- **NCT ID:** NCT07711184
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-06
- **Final completion:** 2029-12
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711184, "A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*